

CSD/BSE&NSE/2025-26
June 20, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding sale of assets of clinical research and bio-analytical studies site (CR Bio) of the Company

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that the Company has entered into an agreement with Chromo Laboratories India Private Limited for the sale of the assets pertaining to its standalone Clinical Research and Bio-analytical unit (‘CR Bio’), for a consideration of ₹16 crore. The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 on the captioned subject is annexed herewith.

We request you to take this information on record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Encl: as above

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSICC, Raidurg, Hyderabad – 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala, Andheri East, Chakala MIDC, Mumbai – 400093, Maharashtra, India.
Tel: +91 22 6153 9999



Sale of assets of CR Bio unit

Sl	Particulars	Details
a	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year	<p>The Company has entered into agreements with Chromo Laboratories India Private Limited for sale of assets of CR Bio unit of the Company for a total consideration of Rs. 16 Crore. CR Bio is a standalone unit and is not part of the core operations of the Company. CR Bio was part of erstwhile Cohance Lifesciences Limited, which merged with the Company effective from May 1, 2025.</p> <p>Revenue from CR Bio unit for FY2025 was Rs.9.8 Crore constituting approximately 0.82% of the Company's standalone revenue (₹1,197.58 crore).</p> <p>Considering the merged entity effective May 1, 2025, the CR Bio unit contributed 0.38% to the combined FY2025 turnover.</p>
b	Date on which the agreement for sale has been entered into	The agreements are executed on June 20, 2025 and shall be subject to customary closing conditions under the said agreements.
c	The expected date of completion of sale/ disposal	Expected to complete in Q2 FY2026, subject to satisfaction of customary closing conditions under the said agreements.
d	Consideration received from such sale/ disposal	The consideration for the sale of assets of CR Bio unit is Rs.16 Crore.
e	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	<p>Chromo Laboratories India Private Limited (CIN: U24231TG2006PTC050452), was incorporated on June 26, 2006 and has its registered office at Plot No. 33, 43 & 44, IDA, Phase II, Pashamylaram, Patancheru Mandal, IDA Pashamailaram, Sangareddy, Patancheru, Telangana, India, 502307.</p> <p>Buyer do not belong or related to the promoter/ promoter group/ group of companies.</p>
f	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	No, the Buyer is not a related party. The transaction has been executed at arm's length.
g	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	<p>Yes, the transaction is outside the Scheme of Arrangement.</p> <p>Provisions of Regulation 37A of the SEBI Listing Regulations are not applicable to the transaction as the sale of assets of CR Bio unit does not qualify to be an "undertaking" in terms of Section 180(1)(a) of the Companies Act, 2013.</p>

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999



h	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity with respect to such slump sale	
	i	<p>Name of the entity(ies) forming part of the sale amalgamation/merger, details in brief such as, size, turnover etc.</p> <p>Seller: Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited) was incorporated on November 6, 2018, and having registered office at 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai, Mumbai, Maharashtra, India, 400093</p> <p>The standalone revenue of the seller for FY2025 was Rs. 1197.58 Crore. Revenue from CR Bio unit for FY2025 was Rs. 9.8 Crore.</p> <p>Buyer: Chromo Laboratories India Private Limited, was incorporated on June 26, 2006 and has its registered office at Plot No. 33, 43 & 44, IDA, Phase II, Pashamylaram, Patancheru Mandal, IDA Pashamailaram, Sangareddy, Patancheru, Telangana, India, 502307.</p>
	ii	<p>Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”</p> <p>Please refer to Clause (f) above for related party confirmation.</p>
	iii	<p>Area of business of the entity(ies)</p> <p>Seller: Seller is <i>inter alia</i> engaged in the business of: (i) contract development and manufacturing organizations; (ii) contract manufacturing; and (iii) analytical services.</p> <p>Buyer: Buyer is <i>inter alia</i> engaged in the business of pharmaceutical products.</p>
	iv	<p>Rationale for amalgamation/merger sale</p> <p>CR Bio is a standalone business unit and is non-core to the Company’s operations. CR Bio was part of erstwhile Cohance Lifesciences Limited, which merged with the Company effective from May 1, 2025.</p>
	v	<p>In case of cash consideration – amount or otherwise share exchange ratio</p> <p>Please refer Clause (d) above.</p>
	vi	<p>Brief details of change in shareholding pattern (if any) of listed entity</p> <p>No change in the shareholding pattern of the Company.</p>

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad – 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai – 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

